Moderna Inc $ 68.72 -0.54 (-0.78%)
Volume:
6,268,420
Avg Vol (1m):
14,905,038
Market Cap $:
27.12 Bil
Enterprise Value $:
24.57 Bil
P/E (TTM):
0.00
P/B:
9.19
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 16.2 | ||
| Equity-to-Asset | 0.85 | ||
| Debt-to-Equity | 0.06 | ||
| Debt-to-EBITDA | -0.37 | ||
| Altman Z-Score | 30.2 | ||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -484.63 | ||
| Net Margin % | -460.36 | ||
| ROE % | -29.17 | ||
| ROA % | -23.38 | ||
| ROC (Joel Greenblatt) % | -181.29 | ||
| 3-Year Revenue Growth Rate | -20.7 | ||
| 3-Year EBITDA Growth Rate | -27.1 | ||
| 3-Year EPS without NRI Growth Rate | -22 |
MRNA
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 45.72 | ||
| PB Ratio | 9.19 | ||
| PS Ratio | 235.34 | ||
| EV-to-EBIT | -51.12 | ||
| EV-to-EBITDA | -54.74 | ||
| EV-to-Revenue | 232.12 | ||
| Current Ratio | 17.3 | ||
| Quick Ratio | 17.3 | ||
| Days Sales Outstanding | 173.61 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 9.17 | ||
| Earnings Yield (Greenblatt) % | -1.97 |